Moonlake Immunotherapeutics (MLTX)

Apr 8, 2025, 3:31 AM EDT - 13 days ago

MoonLake Immunotherapeutics: A Buy At Dips

Apr 3, 2025, 7:00 AM EDT - 18 days ago

MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

Feb 26, 2025, 7:00 AM EST - 7 weeks ago

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Jan 17, 2025, 6:03 PM EST - 3 months ago

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

Jan 8, 2025, 7:00 AM EST - 3 months ago

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Sep 9, 2024, 7:00 AM EDT - 8 months ago

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Jul 18, 2024, 2:19 PM EDT - 9 months ago

MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward

May 16, 2024, 8:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

May 12, 2024, 8:37 AM EDT - 1 year ago

MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion

May 7, 2024, 8:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Apr 10, 2024, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

Apr 10, 2024, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

Mar 10, 2024, 12:00 PM EDT - 1 year ago

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Mar 4, 2024, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

Feb 29, 2024, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

Feb 26, 2024, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

Dec 9, 2023, 6:38 AM EST - 1 year ago

MoonLake Immunotherapeutics Is A Promising Bet On Psoriasis Treatment

Nov 14, 2023, 8:00 AM EST - 1 year ago

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Nov 5, 2023, 11:00 AM EST - 1 year ago

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

Oct 15, 2023, 9:03 AM EDT - 1 year ago

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

Oct 11, 2023, 10:15 AM EDT - 1 year ago

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

Oct 4, 2023, 7:01 AM EDT - 1 year ago

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Sep 27, 2023, 8:00 PM EDT - 1 year ago

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

Sep 6, 2023, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

Aug 27, 2023, 11:54 PM EDT - 1 year ago

Anchored In Innovation: MoonLake Immunotherapeutics Charts A New Course (Rating Upgrade)

Aug 10, 2023, 7:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

Jul 31, 2023, 2:43 PM EDT - 1 year ago

August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge

AAPL AMGN ARDX CELH COIN CSCO CVX

Jul 25, 2023, 8:00 AM EDT - 1 year ago

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

Jul 24, 2023, 2:45 PM EDT - 1 year ago

Strong Mid-Cap Insider Buys: Q2 2023

ABCB ADC CLF CNX DISH EWBC GME

Jul 14, 2023, 3:38 PM EDT - 1 year ago

Exclusive: MoonLake Immunotherapeutics explores sale-sources

Jun 28, 2023, 5:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

Jun 27, 2023, 5:50 PM EDT - 1 year ago

MoonLake: Further Gains Possible With End Of 2023 Data Releases

Jun 26, 2023, 4:01 PM EDT - 1 year ago

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

Jun 25, 2023, 9:00 AM EDT - 1 year ago

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

May 12, 2023, 7:45 AM EDT - 2 years ago

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

May 3, 2023, 6:45 AM EDT - 2 years ago

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

Apr 27, 2023, 9:30 AM EDT - 2 years ago

MoonLake Immunotherapeutics: Cosentyx Rival With Numerically Better Data

Apr 19, 2023, 8:16 AM EDT - 2 years ago

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

Mar 20, 2023, 7:45 AM EDT - 2 years ago

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

Feb 2, 2023, 8:00 AM EST - 2 years ago

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

Dec 14, 2022, 8:00 AM EST - 2 years ago

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

Nov 14, 2022, 8:00 AM EST - 2 years ago

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

Sep 26, 2022, 8:00 AM EDT - 2 years ago

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Jul 26, 2022, 8:00 AM EDT - 2 years ago

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

Jul 21, 2022, 1:15 PM EDT - 2 years ago

HC Wainwright Starts Coverage On This 'Best-In-Class Agent For Inflammatory Disorders

May 31, 2022, 9:24 AM EDT - 3 years ago

Why MoonLake Immunotherapeutics Shares Are Surging Higher Today

May 12, 2022, 7:00 AM EDT - 3 years ago

MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Oct 4, 2021, 7:00 AM EDT - 3 years ago

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

Oct 22, 2020, 5:12 PM EDT - 4 years ago

Helix Acquisition Corp. Announces Closing of $115 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares